Search Results: All recruiting trials found

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

31 trials found

Drug	NCT#	Name	Phase
Imatinib + PDR001	NCT03609424	PDR001 Plus Imatinib for Metastatic or Unresectable GIST	1/2

Imatinib + Selinexor	NCT04138381	Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST)	1/2

Bezuclastinib plus Sunitinib	NCT05208047	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	3

Famitinib	NCT04409223	Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib	3

Imatinib	NCT02260505	Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)	3

Imatinib	NCT02413736	Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST	3

Avelumab + Axitinib	NCT04258956	A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)	2

ctDNA plus Sunitinib or Regorafenib	NCT05366816	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	2

Imatinib	NCT02924714	The Stop-GIST Trial: Discontinuation of Imatinib in Patients With Oligo-metastatic GIST	2

Imatinib	NCT05009927	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	2

Imatinib + Atezolizumab	NCT05152472	A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)	2

Lenvatinib	NCT04193553	Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)	2

Paclltaxel	NCT03944304	Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.	2

Sunitinib + Regorafenib	NCT05366816	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	2

IDRX-42	NCT05489237	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors	1

Pimitesib	NCT05245968	A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)	1

MAAT	NCT04879979	Cognitive Impairment in GIST Patients on Tyrosine Kinase Inhibitor Therapy: Cognitive Behavioral Therapy to Improve Cognitive Symptoms (GIST-MAAT)	0

Imatinib + Sunitinib + Regorafenib	NCT02331914	GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

Surgery	NCT04557969	Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

EDO-S101	NCT03345485	Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors	1/2

Regorafenib + Avelumab	NCT03475953	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	1/2

Belzutifan	NCT04924075	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	2

HER-2 B Cell Peptide	NCT01376505	Vaccine Therapy in Treating Patients With Metastatic Solid Tumors	1

HQP1351	NCT03594422	A Study of HQP1351 in Patients With GIST or Other Solid Tumors	1

Imatinib + Ipilimumab	NCT01738139	Ipilimumab and Imatinib Mesylate in Advanced Cancer	1

INBRX-109 + Temozolomide	NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	1

NB003	NCT04936178	A Study of NB003 in Patients With Advanced Malignancies	1

neoBOMB1	NCT03872778	[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)	1

CS1001 + Regorafenib	NCT04200404	A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors	1/2

Entrectinib	NCT02568267	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	2

LOXO-101	NCT02576431	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	2

Search Results: All recruiting trials found

31 trials found

Drug

NCT#

Name

Phase